Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Benzinga · 2d ago
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.